STOCK TITAN

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Nurix Therapeutics (NRIX) has appointed John Northcott as Chief Commercial Officer. Northcott brings over 20 years of biopharmaceutical experience, notably in commercializing the BTK inhibitor ibrutinib. The appointment comes as Nurix prepares to launch its pivotal clinical program for NX-5948 in chronic lymphocytic leukemia and other potential B-cell malignancies.

Northcott's recent roles include serving as CCO at Arvinas (2022-2024), where he built commercial infrastructure for a novel breast cancer treatment, CCO at Nektar Therapeutics (2019-2022), and CCO at Pharmacyclics (2015-2019), where he led the successful commercialization of ibrutinib. His experience spans both pre-launch planning and on-market commercialization in hematology, oncology, and other therapeutic areas.

Nurix Therapeutics (NRIX) ha nominato John Northcott come Chief Commercial Officer. Northcott porta con sé oltre 20 anni di esperienza nel settore biofarmaceutico, in particolare nella commercializzazione dell'inibitore BTK ibrutinib. Questa nomina avviene mentre Nurix si prepara a lanciare il suo programma clinico cruciale per NX-5948 nella leucemia linfatica cronica e altre potenziali neoplasie a cellule B.

I recenti ruoli di Northcott includono la carica di CCO presso Arvinas (2022-2024), dove ha costruito l'infrastruttura commerciale per un nuovo trattamento contro il cancro al seno, CCO presso Nektar Therapeutics (2019-2022) e CCO presso Pharmacyclics (2015-2019), dove ha guidato la commercializzazione di successo di ibrutinib. La sua esperienza copre sia la pianificazione pre-lancio che la commercializzazione sul mercato in ematologia, oncologia e altre aree terapeutiche.

Nurix Therapeutics (NRIX) ha nombrado a John Northcott como Director Comercial. Northcott aporta más de 20 años de experiencia en el biopharma, notablemente en la comercialización del inhibidor de BTK ibrutinib. Esta designación se produce mientras Nurix se prepara para lanzar su programa clínico fundamental para NX-5948 en leucemia linfocítica crónica y otras posibles malignidades de células B.

Los roles recientes de Northcott incluyen servir como CCO en Arvinas (2022-2024), donde construyó la infraestructura comercial para un novedoso tratamiento contra el cáncer de mama, CCO en Nektar Therapeutics (2019-2022) y CCO en Pharmacyclics (2015-2019), donde lideró la exitosa comercialización de ibrutinib. Su experiencia abarca tanto la planificación previa al lanzamiento como la comercialización en el mercado en hematología, oncología y otras áreas terapéuticas.

Nurix Therapeutics (NRIX)가 John Northcott를 최고상업책임자(Chief Commercial Officer)로 임명했습니다. Northcott는 BTK 억제제 이부티닙(ibrutinib)의 상업화에서 특히 20년 이상의 생명공학 경험을 보유하고 있습니다. 이 임명은 Nurix가 만성 림프구 leukemias 및 기타 잠재적인 B세포 악성 종양을 위한 NX-5948의 주요 임상 프로그램을 시작할 준비를 하고 있는 가운데 이루어졌습니다.

Northcott의 최근 역할로는 Arvinas(2022-2024)에서 CCO로 자리하면서 새로운 유방암 치료법을 위한 상업적 인프라 구축, Nektar Therapeutics(2019-2022) 및 Pharmacyclics(2015-2019)에서 CCO로 활동하며 이부티닙의 성공적인 상업화를 주도한 바 있습니다. 그의 경험은 혈액학, 종양학 및 기타 치료 분야에서의 출시 전 계획 및 시장 상업화를 모두 포함합니다.

Nurix Therapeutics (NRIX) a nommé John Northcott au poste de Directeur Commercial. Northcott dispose de plus de 20 ans d'expérience dans le secteur biopharmaceutique, notamment dans la commercialisation de l'inhibiteur BTK ibrutinib. Cette nomination intervient alors que Nurix se prépare à lancer son programme clinique fondamental pour NX-5948 dans la leucémie lymphoïde chronique et d'autres malignités potentielles des cellules B.

Les rôles récents de Northcott incluent des postes de CCO chez Arvinas (2022-2024), où il a construit l'infrastructure commerciale pour un nouveau traitement du cancer du sein, CCO chez Nektar Therapeutics (2019-2022) et CCO chez Pharmacyclics (2015-2019), où il a dirigé la commercialisation réussie de l'ibrutinib. Son expérience couvre à la fois la planification avant le lancement et la commercialisation sur le marché en hématologie, oncologie et d'autres domaines thérapeutiques.

Nurix Therapeutics (NRIX) hat John Northcott zum Chief Commercial Officer ernannt. Northcott bringt über 20 Jahre Erfahrung im Bereich Biopharma mit, insbesondere in der Kommerzialisierung des BTK-Inhibitors Ibrutinib. Diese Ernennung erfolgt, während sich Nurix darauf vorbereitet, sein wegweisendes klinisches Programm für NX-5948 bei chronischer lymphatischer Leukämie und anderen potenziellen B-Zell-Malignitäten zu starten.

Zu Northcotts jüngsten Tätigkeiten gehören die Position als CCO bei Arvinas (2022-2024), wo er die kommerzielle Infrastruktur für eine neuartige Behandlung von Brustkrebs aufbaute, CCO bei Nektar Therapeutics (2019-2022) sowie CCO bei Pharmacyclics (2015-2019), wo er die erfolgreiche Kommerzialisierung von Ibrutinib leitete. Seine Erfahrung reicht von der Planung vor dem Markteintritt bis zur Markteinführung in der Hämatologie, Onkologie und anderen Therapeutikbereichen.

Positive
  • Appointment of experienced CCO with proven track record in commercializing BTK inhibitors
  • Strategic timing of hire coincides with pivotal clinical program launch for NX-5948
  • New CCO brings specific expertise in building commercial infrastructure for novel oncology drugs
Negative
  • None.

Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinib

SAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of John Northcott as chief commercial officer (CCO). Mr. Northcott has over 20 years of commercial experience, including as CCO for several biotechnology companies building commercial organizations and successfully commercializing the first marketed BTK inhibitor ibrutinib.

“We are thrilled to have John join the Nurix team as we prepare to launch our pivotal clinical program for NX-5948 in chronic lymphocytic leukemia and potentially other B-cell malignancies,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “John’s experience commercializing the BTK inhibitor ibrutinib as well as his experience building commercial teams ahead of potential launches for novel oncology agents make him the ideal chief commercial officer for Nurix at this stage in our growth.”

“Joining Nurix at such a pivotal time is an incredible opportunity,” said Mr. Northcott. “I have rarely seen an investigational new drug deliver such impressive response rates in patients who have essentially exhausted all other approved treatment options. I look forward to leveraging my experience in commercial strategy and execution to bring NX-5948 to patients, and to further establish Nurix as a leader in the field of targeted protein degradation.”

Mr. Northcott has extensive U.S. and global commercial leadership experience, including both pre-launch planning and on-market commercialization in hematology, oncology and a wide range of other therapeutic areas. From 2022 through 2024, Mr. Northcott served as CCO of Arvinas, where he built a commercial infrastructure in support of the potential launch of a novel first-in-class estrogen receptor degrader for the treatment of breast cancer. From 2019 to 2022, Mr. Northcott served as CCO of Nektar Therapeutics, and from 2015 to 2019, he served as the CCO of Pharmacyclics, where he led the successful commercialization of the first marketed BTK inhibitor ibrutinib. Prior to Pharmacyclics, Mr. Northcott was CCO at Lexicon Pharmaceuticals from 2013 to 2015.

About NX-5948
NX-5948 is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK. NX-5948 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. Nurix has previously reported that NX-5948 showed a 75.5% objective response rate in a heavily pretreated patient population including patients with mutations in BTK associated with resistance to inhibitors and other poor prognostic genetic markers. Additional information on the ongoing clinical trial can be accessed at clinicaltrials.gov (NCT05131022).

About Nurix

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding Nurix’s plans to advance NX-5948 into pivotal clinical testing, the potential of Nurix’s drug candidates, and the expected contributions Mr. Northcott will bring to Nurix, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the period ended August 31, 2024, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix’s stock price. Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

Contacts:

Investors

Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com

Media

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com


FAQ

What is John Northcott's experience with BTK inhibitors before joining NRIX?

John Northcott led the successful commercialization of the first marketed BTK inhibitor ibrutinib while serving as CCO at Pharmacyclics from 2015 to 2019.

What is the main focus of NRIX's upcoming clinical program?

NRIX is preparing to launch a pivotal clinical program for NX-5948 in chronic lymphocytic leukemia and potentially other B-cell malignancies.

What were John Northcott's most recent positions before joining NRIX?

Before joining NRIX, Northcott served as CCO at Arvinas (2022-2024), Nektar Therapeutics (2019-2022), and Pharmacyclics (2015-2019).

What commercial infrastructure did Northcott develop at Arvinas?

At Arvinas, Northcott built commercial infrastructure to support the potential launch of a novel first-in-class estrogen receptor degrader for breast cancer treatment.

Nurix Therapeutics, Inc.

NASDAQ:NRIX

NRIX Rankings

NRIX Latest News

NRIX Stock Data

1.39B
69.46M
1.45%
97.77%
13.88%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO